Lung cancer remains the most diagnosed cancer in the world, with a high mortality rate
and fewer therapeutic options. The most common lung cancer is non-small cell, consisting of adenocarcinoma,
squamous cell carcinoma and large cell lung carcinoma. As per all solid tumours, the
changes that occur for the initiation and metastasis of lung cancer can be described using the EMT
(epithelial mesenchymal transition). Cells progressing through EMT lose their epithelial cell characteristics,
expressing more mesenchymal markers and are phenotypically different. The transition can
be controlled by changes in various pathways, such as TGF-β, PI3K, MAPK, Hedgehog and Wnt.
The changes in those pathways can be controlled epigenetically, via DNA methylation, histone
modifications or changes in small/non-coding RNA. We will describe the epigenetic changes that
occur in these pathways and how we can consider novel methods to generate a synthetic lethality
target in an epigenetically regulated pathway in EMT.
Keywords: NSCLC, EMT regulation, epigenetics, targeted therapy, lung cancer, tumor.
Rights & PermissionsPrintExport